SOPHiA Genetics SA [SOPH] stock is trading at $4.01, up 1.78%. An important factor to consider is whether the stock is rising or falling in short-term value. The SOPH shares have gain 9.86% over the last week, with a monthly amount glided 26.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SOPHiA Genetics SA [NASDAQ: SOPH] stock has seen the most recent analyst activity on December 18, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $11. Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 07, 2024, and dropped its price target to $5. On June 27, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $6 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $8 on November 29, 2023. BTIG Research started tracking with a Buy rating for this stock on January 03, 2023, and assigned it a price target of $6. In a note dated November 23, 2022, Credit Suisse initiated an Neutral rating and provided a target price of $2 on this stock.
SOPHiA Genetics SA [SOPH] stock has fluctuated between $2.70 and $7.37 over the past year. Currently, Wall Street analysts expect the stock to reach $5.67 within the next 12 months. SOPHiA Genetics SA [NASDAQ: SOPH] shares were valued at $4.01 at the most recent close of the market. An investor can expect a potential return of 41.4% based on the average SOPH price forecast.
Analyzing the SOPH fundamentals
SOPHiA Genetics SA [NASDAQ:SOPH] reported sales of 64.49M for the trailing twelve months, which represents a drop of -2.76%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.06%, Pretax Profit Margin comes in at -1.1%, and Net Profit Margin reading is -1.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.55 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.81 points at the first support level, and at 3.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.13, and for the 2nd resistance point, it is at 4.25.
Ratios To Look Out For
For context, SOPHiA Genetics SA’s Current Ratio is 3.80. On the other hand, the Quick Ratio is 3.59, and the Cash Ratio is 3.1. Considering the valuation of this stock, the price to sales ratio is 4.07, the price to book ratio is 2.35.
Transactions by insiders
Recent insider trading involved PHILIPPE MENU, Officer, that happened on Jan 27 ’25 when 7500.0 shares were purchased. Director, JURGI CAMBLONG completed a deal on Jan 27 ’25 to buy 28500.0 shares. Meanwhile, Director JURGI CAMBLONG bought 18758.0 shares on Jan 24 ’25.
